LCT to start clinical trial of Type 1 diabetes treatment

Living Cell Technologies Ltd (ASX:LCT) today announced its DiabeCell^® Type 1 diabetes treatment has been approved for a Phase I/IIA clinical trial in Russia designed according to FDA guidelines and monitored by a Boston-based Contract Research Organisation.

DiabeCell^® is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. The natural neo-natal pig islet cells are encased in capsules that allow insulin to be released but prevents the patient's immune system from attacking the cells. The islets are simply injected into the body and produce insulin as needed in response to the levels of glucose in the blood. This mimics the normal insulin release that occurs in healthy non-diabetic people and thus helps regulate blood glucose levels in those suffering from Type 1 diabetes.

The trial may enable an expedited route to commercialisation within the region. Initial response to treatment will be evident within six months. The trial will use cells from fully-screened and biocertified pigs, bred according to US FDA (Food and Drug Administration) guidelines.